Abans Financial Services Ltd

AI
Abans Financial Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Abans Financial Services Ltd

₹ 202 0.35%
20 Aug - close price
abansholdings.com BSE: 543712 NSE: AFSL
About

Incorporated in 2009, Abans Financial Services Ltd provides services such as Institutional Broking, Asset Management, Financial Lending, Treasury operations, and Remittance Services[1]

Key Points

Business Overview:[1]
AFSL used to be a commodities trading
company, but has diversified into a multi-
asset and multinational financial services company mainly segmented under – Agency Business, Finance Business, and Capital
Business. It caters to financial businesses
viz. Institutional Broking, Asset Management, Financial Lending, Treasury operations and Remittance Services.

Website BSE NSE
  • Market Cap ₹ 1,023 Cr.
  • Current Price ₹ 202
  • High / Low ₹ 241 / 194
  • Stock P/E 7.97
  • Book Value ₹ 247
  • Dividend Yield 0.00 %
  • ROCE 7.92 %
  • ROE 8.29 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.82 times its book value
  • Company's working capital requirements have reduced from 85.3 days to 12.0 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 9.20% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Financial Services Financial Services Finance Holding Company

Part of BSE Financial Services

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
252 365 506 252 296 641 1,280 1,063 1,894 6,832 6,495 8,708 3,713
218 327 468 215 252 595 1,228 1,016 1,842 6,784 6,451 8,693 3,613
Operating Profit 33 39 38 37 44 46 52 48 51 48 44 16 100
OPM % 13% 11% 8% 15% 15% 7% 4.0% 4.5% 2.7% 0.7% 0.7% 0.2% 2.7%
4 0 1 0 0 1 0 1 2 2 1 1 1
Interest 13 14 13 12 15 12 17 15 12 9 9 12 13
Depreciation 0 0 0 0 0 0 0 0 0 0 0 1 1
Profit before tax 24 25 26 25 29 35 35 33 41 40 36 4 86
Tax % 14% 6% 8% 16% 16% 22% 24% 9% 21% -6% 4% 188% 24%
21 23 24 21 24 27 27 30 33 42 34 -4 66
EPS in Rs 3.84 4.26 4.32 3.89 4.43 5.06 5.13 5.61 5.92 7.55 6.33 -0.76 12.19
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
4,377 2,771 1,331 645 1,163 1,380 3,281 23,874 25,747
4,321 2,675 1,250 554 1,078 1,228 3,091 23,715 25,541
Operating Profit 57 96 81 91 86 152 190 158 206
OPM % 1.3% 3.5% 6% 14% 7% 11% 6% 0.7% 0.8%
0 1 0 2 0 0 2 6 4
Interest 17 53 31 26 10 52 59 41 42
Depreciation 2 1 1 1 1 1 1 2 3
Profit before tax 38 42 49 66 76 100 132 121 166
Tax % 6% 7% 7% 6% 7% 11% 18% 13%
36 39 46 62 70 89 109 105 138
EPS in Rs 35,330.00 112.89 9.04 12.27 12.92 16.30 20.15 19.01 25.31
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 78%
3 Years: 174%
TTM: 428%
Compounded Profit Growth
10 Years: %
5 Years: 18%
3 Years: 14%
TTM: 17%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -10%
1 Year: -9%
Return on Equity
10 Years: %
5 Years: 9%
3 Years: 9%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.01 3 9 9 10 10 10 10
Reserves 370 497 553 622 817 921 1,064 1,240
384 319 268 86 441 929 834 744
333 395 352 452 595 1,036 1,151 913
Total Liabilities 1,086 1,213 1,182 1,169 1,863 2,896 3,060 2,907
27 21 20 20 19 21 22 33
CWIP 0 0 0 0 0 0 0 0
Investments 39 47 60 97 570 1,007 974 1,314
1,020 1,144 1,101 1,052 1,274 1,869 2,064 1,560
Total Assets 1,086 1,213 1,182 1,169 1,863 2,896 3,060 2,907

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-126 18 62 -12 211 33 -119 505
1 -64 -4 -35 -466 -446 156 -278
185 22 66 -21 418 403 -150 -13
Net Cash Flow 59 -24 124 -67 163 -10 -112 214
Free Cash Flow -128 14 62 -12 211 32 -121 502
CFO/OP -215% 21% 80% -8% 252% 29% -52% 342%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 20 57 94 169 78 58 37 1
Inventory Days 6 4 7 42 22 18 2 0
Days Payable 14 30 17 76 28 13 6 1
Cash Conversion Cycle 11 31 85 135 72 63 34 -0
Working Capital Days 55 102 176 319 128 169 75 12
ROCE % 11% 9% 10% 8% 9% 10% 8%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Interest Margin (NBFC)
%

Log in to view insights

Please log in to see hidden values.

Login
Total Assets Under Management (AUM)
INR lakhs
Brokerage, Payment Processing & Advisory Income
INR lakhs
Fee-based Investment Services Revenue (Core)
INR lakhs
Global Arbitrage Fund (GAF) AUM
INR Crs
Lending & Credit Solutions Revenue (Core)
INR lakhs
Loan Book (NBFC)
INR lakhs
Principal Investment & Treasury Revenue (Core)
INR lakhs

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.09% 72.09% 72.09% 72.09% 72.02% 71.50% 71.48% 71.47% 71.43% 71.36% 71.36% 71.11%
11.72% 11.58% 11.47% 10.42% 11.07% 12.86% 15.11% 15.70% 16.14% 17.03% 19.02% 20.71%
0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.05% 0.00% 0.00% 0.00% 0.00%
16.19% 16.34% 16.45% 17.50% 16.88% 15.64% 13.41% 12.78% 12.42% 11.61% 9.61% 8.18%
No. of Shareholders 14,52413,19312,87111,45915,51316,53716,78616,21516,14015,47314,63514,110

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls